Conquering allograft rejection remains an elusive goal in spite of recent breakthroughs in the field of immunosuppression. Much of the problem lies in the toxicity and side-effects of long-term use of systemic immunosuppressant drugs, which are sometimes ineffective in controlling rejection, but also hinder establishment of transplant tolerance. In this review, we discuss novel technologies that use grafts engineered with immunomodulatory molecules as a means of inducing tolerance.
INTRODUCTION
Despite impressive advancements in the development of new immunosuppressants targeting the effector mechanisms of graft rejection, indefinite graft survival remains an unattainable goal because of chronic rejection. Currently, this necessitates the use of standard maintenance immunosuppression for the graft life. However, the chronic use of immunosuppression leads to drug-related toxicities and immune incompetence associated with opportunistic infections and malignancies. Moreover, the continuous use of standard immunosuppression has dual disadvantages: it does not always control acute graft rejection, and contributes to chronic rejection by interfering with the development of tolerogenic mechanisms. The reduction or elimination of longterm immunosuppressants is a difficult barrier to overcome because of persistent generation and high frequencies of alloantigen-specific pathogenic CD4 þ and CD8 þ T effector (Teff) cells in the absence of active tolerogenic mechanisms, such as protective regulatory T cells, in the recipient.
There is overwhelming evidence in the current literature pointing to localization of pathogenic and tolerogenic immune responses in the target tissues [1] . These findings emphasize the importance of understanding the nature of immune responses within the graft, and thus the exciting possibility of targeted manipulation of intra-graft immune responses for achieving safe, long-term graft survival without chronic use of immunosuppression. We herein review and discuss several novel technologies designed to engineer grafts with biologics for immunomodulation to overcome rejection. The emphasis will primarily be on the review of recent literature focusing on the application of these technologies to cellular and tissue allografts with a limited reference to solid organs.
IMMUNOMODULATION USING GRAFTS ENGINEERED TO DISPLAY BIOLOGICS ON THEIR SURFACE
Localizing and limiting the tolerogenic mechanisms to the graft, while leaving the systemic immune responses unrelated to the graft largely intact is best accomplished using the graft itself as a tolerogenic entity. This can be best achieved by modifying the surface of the graft with immunomodulatory biologics involved in induction of tolerance. This approach is conceptually attractive and provides two distinct advantageous over systemic treatment of the graft recipients: the modified graft operating as an immunomodulatory entity has better chance to overcome rejection by local graft protection through immunoregulatory, rather than destructive, alloreactive responses; and the invoked immunoregulatory responses may be localized to the graft, thereby retaining better immune competency. Such localized immune strategies have been utilized in nature, as when bacteria encapsulate themselves to avoid immune protection, or when immune-privileged organs maintain increased expression of immunoregulatory factors, such as transforming growth factor (TGF-b) and FasL, to protect against excess inflammation.
In this review, we will describe two distinct approaches targeting the engineering of grafts with biologics for immunomodulation: those using various chemistries to modify the surface of pancreatic islets with immunomodulatory molecules, and the ProtEx technology developed by Yolcu et al. [2] as a practical and targeted approach for positional display of immunological ligands on the surface of cells, tissues, and solid organs.
IMMUNOMODULATION WITH THROMBOMODULIN
The transplantation of pancreatic islets into type I diabetic patients to achieve euglycemia is an important therapeutic approach to reconstitute endogenous insulin homeostasis. In the clinical setting, islets are prevalently transplanted through the portal vein, initiating an immediate blood-mediated inflammatory reaction (IBMIR) to the graft [3, 4] . IBMIR is responsible for 50-80% loss of infused islets, a major obstacle for early islet engraftment [4] [5] [6] . Significant islet loss caused by IBMIR necessitates transplantation of islets from several donors to achieve requisite islet dose needed for euglycemia. The canonical features of this thrombotic/inflammatory reaction are rapid activation of platelets, coagulation and complement, resulting in acute leukocyte infiltration and islet damage. In fact, coagulation is fostered by the grafted islets through tissue factors expressed in response to stimuli associated with donor death, islet isolation and local injury to endothelial cells of islet microvasculature [4] . Tissue factor mediates the conversion of prothrombin to thrombin, initiating the coagulation cascade, innate, and proinflammatory responses.
This initial period of islet destruction can be ameliorated by natural anticoagulants in the form of heparin sulfate or thrombomodulin. Thrombomodulin activates protein C following pairing with thrombin, reducing blood clotting, and inflammation [7] [8] [9] [10] through negative regulation of the coagulation pathway, inhibition of innate, and adaptive immune responses [11] and expansion of CD4 þ CD25 þ FoxP3 þ T regulatory (Treg) cells [12] [13] [14] . Focusing on the therapeutic efficacy of thrombomodulin in prevention of IBMIR, systemic administration of liposomal thrombomodulin was shown to significantly improve intraportal allogeneic islet engraftment and survival in models of murine chemical diabetes [7] . These positive effects
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of modulation with thrombomodulin were associated with significant reduction in fibrin deposition, graft-infiltrating neutrophils, and TNFa and IL-b levels in the liver.
Further, procedural improvements are used to directly engineer islet surface with thrombomodulin such as chemical conjugation performed by Chaikof's group [15, 16] . These approaches involve attachment of azido-functionalized thrombomodulin molecule onto the islet surface (using Staudinger ligation to a bifunctional poly(ethylene glycol) [15] and streptavidin-biotin bridge [16, 17] ). Islets engineered with thrombomodulin displayed increased activated protein C production and reduced thrombogenicity [7, 15, 16] . In another approach, conjugation of both thrombomodulin and urokinase onto the surface of islets using polyethylene glycol-conjugated phospholipids was shown to have no detrimental impact on islet function [18] . Although promising, the use of these approaches to overcome IBMIR and enhance graft survival in vivo remains to be demonstrated.
IMMUNOMODULATION WITH TGF-b
Numerous preclinical models showed that longterm tolerance to allografts is strongly associated with the presence of Treg cells within graft microenvironment [1, [19] [20] [21] . Although intuitive, the mechanistic basis of this observation is not fully elucidated and may be caused by presentation of alloantigens by the graft and induce localized amplification of Treg cells. This notion is consistent with studies demonstrating that antigen-specific Treg cells have better efficacy than polyclonal cells in graft protection from rejection [22] . In addition, it has been demonstrated that Treg cells traffic to and reside in the graft, thus preventing rejection by effector cells and contributing to long-term graft survival [1, 19, 20, 23] . Indeed, coating the surface of pancreatic islets with Treg cells prolongs survival in allogeneic recipients [24] . Therefore, localized immunomodulation using biologics involved in generation of Treg cells presents an important approach with a significant potential of efficacy to induce tolerance.
TGF-b1 is critical for the development, expansion, and function of Treg cells. A series of recent studies has shown the capacity of TGF-b1 to mediate tolerance to allo-and self-antigens in various transplantation and autoimmune settings. For example, ectopic expression of TGF-b in heart allografts resulted in long-term survival [25] , and self-tolerance established using anti-CD3 antibodies was found to depend on TGF-b in non-obese diabetic (NOD) mice [26] . These effects may be primarily mediated by the critical role of TGF-b1 in the development, homeostasis, and expansion of Treg cells. Consistently, mice deficient for TGF-b1 display reduced Treg numbers in the periphery because of TGF-b1 regulation of FoxP3 [27] . TGF-b1 also plays an important role in the homeostasis and function of Treg cells in NOD mice [28] . NOD mice have significantly reduced absolute numbers of Treg cells as compared with disease-resistant strains [29, 30] . This reduction results from a decline in the cell surface expression of TGF-b1, which in turn results in reduced expression of FoxP3 and altered function of Treg cells that coincide with the disease onset [28, 29, 31] . TGF-b1 also plays an important role in the conversion of naïve CD4 þ CD25 À T conventional cells into Treg cells by inducing FoxP3 expression [32] [33] [34] . Interestingly, a recent study has shown that transient expression of TGF-b1 in inflamed islets of NOD was effective in delaying the disease, not by the enhancement of Treg cells, but by blocking the development and maintenance of pathogenic CD8 þ Teff cells [35] . Taken together, these studies demonstrate that TGF-b1 confers immune regulation at multiple levels.
Systemic use of TGF-b1 for immunomodulation has been associated with fibrosis that negatively impacts long-term graft survival [36] . This negative effect of TGF-b1 can potentially be ameliorated by immobilizing this molecule on the target cells/tissues. To test the feasibility and efficacy of engineering the cell surface with TGF-b1 as a means of immunomodulation, Yang et al. generated a TGF-b1 chimeric isoform, which has a 1-methyl-2diphenylphosphino-terephthalate moiety, allowing its binding to polyethylene glycol (PEG)lated cells or beads through Staudinger ligation [37] . Antigenpresenting cells coated with the TGF-b1 protein were able to convert conventional CD4 þ T cells into induced Treg cells in response to antigens. The engineered cells were also effective in converting polyclonal naïve CD4 þ T cells into nonspecific Treg cells in response to costimulation with aCD3/CD28 beads. Induced Treg cells were able to suppress the proliferation of naïve CD4 þ T cells in a manner similar to that achieved using naturally occurring Treg cells. However, the efficacy of allografts engineered with TGF-b1 in overcoming rejection remains to be demonstrated.
PROTEX TECHNOLOGY AS AN EFFECTIVE AND PRACTICAL MEANS OF TRANSIENTLY DISPLAYING IMMUNOLOGICAL LIGANDS ON BIOLOGICAL MEMBRANES FOR IMMUNOMODULATION
Immune responses are initiated, coordinated, and resolved by complex interactions between cell surface receptors and ligands. Therefore, Yolcu et al. [2] envisioned that transient display of immunological ligands on the cell surface may provide an effective means of immunomodulation and designed a transient protein display technology called ProtEx. The concept involves generation of chimeric proteins composed of a functional domain of immunological ligands fused to a modified form of streptavidin (SA). These proteins can then be displayed on the surface of any biological membrane by taking advantage of the high-affinity interaction (K d ¼ 10 -15 mol/l) between biotin and streptavidin (Fig. 1) . The process of tissue engineering is practical, performed within 2.5 h, and has an almost absolute efficiency in decorating the targeted tissues. Furthermore, this technology allows for simultaneous display of several chimeric immunological ligands on the cell surface at desired densities with complementary/synergistic functions for better immunomodulatory efficacy [38] . Most importantly, the transient presence of immunological ligands on the cell surface may also obviate the undesired effects arising from gene therapybased long-term expression of immunological ligands having pleiotropic functions.
Chimeric proteins exist as tetramers and oligomers, owing to the structural features of streptavidin, which forms stable tetramers and oligomers under physiological conditions [39] . SA-chimeric immunological proteins were demonstrated to have robust activity whether displayed on the cell membrane or in soluble forms [2] . The improved immunological function of the chimeric ligands as compared with the soluble forms of natural ligands is conceivably because of their ability to oligomerize and crosslink their respective receptors on immune cells for better signal transduction. Immune decisions are made through cell surface receptor/ligand interactions and such interactions are short in duration (minutes to hours). Therefore, the persistence of chimeric immunological ligands on the cell surface for days, if not hours, is sufficient for effective transduction of immunological signals and driving the ensuing immune responses.
SYSTEMIC IMMUNOMODULATION WITH SA-FASL-ENGINEERED CELLS
Activation-induced cell death is critical to immune homeostasis, tolerance to self-antigens, and acquired tolerance to transplantation antigens [40, 41] . Fas/FasL interaction plays an important role in activation-induced cell death [42] [43] [44] [45] [46] [47] . As such, this molecule has been extensively exploited for tolerance induction to self-and alloantigens using gene therapy [47] [48] [49] [50] . Ectopic, persistence expression of FasL in cells and tissues of interest using gene therapy for immunomodulation is technically challenging and imposes safety concerns. However, FasL can transiently be displayed as a protein on any biological membrane, such as cells, pancreatic islets, and vascular endothelium [21, 51] , using the ProtEx technology. This approach benefits from the advantage of using SA-FasLengineered cells, tissues, or solid organs for targeted delivery of apoptotic signals in responding alloreactive cells, thereby avoiding nonselective immune suppression.
Yolcu et al. [2] generated an SA-chimeric FasL molecule (SA-FasL) and used the ProtEx technology to display this protein on the surface of various cells for immunomodulation in autoimmunity and transplantation settings. Graft recipients systemically treated with SA-FasL-engineered donor splenocytes achieved tolerance to cardiac and pancreatic islet allografts in the absence of chronic immunosuppression [21, 52] . In addition to targeted depletion of effector cells, tolerance was maintained by induction/expansion of Treg cells [21, 52] , which are relatively resistant to apoptosis by SA-FasL [17] . This observation resulted in the opportunity of engineering Treg cells with SA-FasL to improve their regulatory function. Treg cells displaying SA-FasL on their surface, referred to as killer Treg cells, had robust regulatory function as compared with unmodified Treg cells [53] . Importantly, SA-FasLengineered Treg cells when adoptively transferred into prediabetic and new onset diabetic NOD mice homed to the pancreas and regional lymph nodes, proliferated, and induced apoptosis in Teff cells, resulting in delayed and lower incidence of diabetes as compared with controls [53, 53, 54 && ]. Similar efficacy of adoptively transferred SA-FasL-engineered Treg cells was also shown for established inflammatory colitis [55] and acute mouse graft-versus-host disease [56] .
LOCALIZED IMMUNOMODULATION WITH SA-FASL-ENGINEERED PANCREATIC ISLETS AND CARDIAC GRAFTS
The ProtEx technology to engineer target cells, tissues, and organs with SA-FasL for localized immunomodulation has significant potential for translational efficacy and safety. Quite extensive studies showed that pancreatic islets from various species can be effectively engineered with SA-FasL without a detrimental effect on their viability, function, and in-vivo engraftment. Islets engineered with SA-FasL, when transplanted under a transient coverage of rapamycin, had robust efficacy in inducing tolerance in a chemically diabetic allogeneic Novel technologies to engineer graft Woodward et al.
mouse model [21, 57] . This protocol was also effective in preventing the rejection of xenogeneic rat islets transplanted into mice (Zhao et al., manuscript in preparation). Recipients of long-term islet grafts had almost normal peripheral responses to donor antigens in ex vivo mixed lymphocyte assays and rejected donor skin grafts in an acute fashion. Importantly, the frequency of Treg cells was increased in graft-draining lymph nodes and within the graft. Depletion of Treg cells early or late posttransplantation resulted in islet graft rejection, demonstrating the importance of these cells for the induction as well as maintenance of tolerance. In an adoptive transfer study, Treg cells isolated from graft-draining lymph nodes were effective in preventing the rejection of unmodified donor islets [21] . These observations indicate the localized nature of tolerance, which was further confirmed by demonstrating that long-term graft survivors rejected a second set unmodified donor islet grafts transplanted under the contralateral kidney capsule [21] . Interestingly, local tolerance was so robust that rejection of the second set of islet grafts did not affect the survival of the long-term primary grafts (>100 days).
ProtEx technology is not only applicable to engineering cells and tissues, but also organs. Ex-vivo engineering of the heart by perfusion with reactive biotin followed by SA-FasL protein under conditions of extracorporeal organ preservation resulted in effective display of the protein on heart vasculature with a half-life of 9 days in vivo. The engineering process did not significantly affect the function of the heart nor showed toxicity as demonstrated by the indefinitely survival of the engineered heart in syngeneic recipients [51] . Most significant was the ability of the SA-FasL-engineered heart to overcome acute rejection in allogeneic recipients [51] . Taken together, these data demonstrate the utility of ProtEx technology as a practical, well tolerated, and effective alternative to DNAbased gene therapy for engineering cells, tissues, and organ for immunomodulation with demonstrated efficacy and potential application to the treatment of various acquired immune disorders and graft rejection.
CONCLUSION
Although current clinical practices in transplantation focus on the systemic nonspecific control of the immune system to achieve graft survival, targeted approaches using engineered cells, tissues, and vasculature of solid organs may achieve safer and better outcomes by controlling early inflammation and inducing active immunoregulatory mechanisms. Immunomodulatory molecules such as SA-FasL and TGF-b, displayed on biological surfaces of the grafts may confer localized immune privilege and long-term survival without the need for chronic immunosuppression. Simultaneous transient display of multiple proteins with synergistic mechanisms of action has significant potential for clinical success. In this context, the ProtEx technology presents a novel and practical approach with demonstrated efficacy in inducing robust tolerance at the local and systemic levels in preclinical models. The translation of this concept to the clinic and its Biological surfaces of interest are modified with biotin followed by decoration with SA-chimeric proteins under physiological conditions. This concept is schematically shown for pancreatic islets, but is also applicable to cells, tissues, and solid organs.
efficacy are exciting future propositions. If effective in the clinic, this concept will have a significant impact on clinical practice of transplantation.
